依班膦酸钠治疗97例骨转移瘤疼痛的临床观察  

Clinical Evaluation of Ibandronate in 97 Patients with Cancer and Lytic Bone Metastases

作　　者：戴广海[1] 焦顺昌[1] 李方[1] 杨俊兰[1] 姜少灏[1] 

机构地区：[1]解放军总医院肿瘤内科,北京市100853

出　　处：《中国肿瘤临床》2004年第5期267-270,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:评价国产依班膦酸钠(Ibandronate)治疗恶性肿瘤高钙血症和骨转移骨痛的疗效和不良反应;同时和帕米膦酸二钠进行疗效和不良反应比较。方法:高钙血症患者应用依班膦酸钠4mg,单次静脉滴注,观察3周内血钙变化;骨痛患者随机分配至A组或B组,A组单次静脉滴注依班膦酸钠4mg,B组单次静脉滴注帕米膦酸二钠90mg,观察3周内骨痛变化情况。结果:97例患者入组,可评价疗效93例,5例高钙血症患者依班膦酸钠治疗后血钙水平均明显下降,有效率为100%(5/5)。骨转移疼痛患者中A组治疗有效率为73.5%,B组为59.0%,经统计学处理两组之间无明显差异。两组不良反应基本类似,B组发热发生率略高于A组。结论:依班膦酸钠对于恶性肿瘤骨转移所引起的骨痛和高钙血症具有较好的治疗作用,不良反应较轻,与帕米膦酸钠比较,骨痛缓解率和不良反应基本相似。Objective: To Evaluated therapeutic effect and toxicity of Ibandronate for patients with cancer and lytic bone metastases. Methods: 7 patients with hypercalcemia were treated with Ibandronate; 50 patients were randomized to the arm A(Ibandronate group) and received Ibandronate 4mg; 40 patients were randomized to the arm B(pamidronate group) and received pamidronate 90mg. Results: Response rate were 100% in 5 evaluated patients with hypercalcemia. Response rate of bone pain were 73.5% in A group and 59.0% in B group(P>0.05). Toxicity including mild fever ,nausea, vomiting, myalgia. Conclusions: Ibandronate can decrease serum calcium and relive bone pain ,similar to pamidronate.

关 键 词：骨转移 依班膦酸钠 高钙血症 骨痛 

分 类 号：R730.5[医药卫生—肿瘤]